Physician profile
David Harrison
NPI 1619949039
$2,439.21
in general payments reported to CMS, 2019-2025
27 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $41.35 · 2021: $21.86 · 2022: $357 · 2023: $667 · 2024: $649 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $642.38 | 2023-2024 | Accrufer |
| Abbvie INC. | $328.93 | 2019-2023 | |
| Coopersurgical, INC. | $187.15 | 2022-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $185.91 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $124.83 | 2023-2024 | Myfembree |
| Pfizer INC. | $106.03 | 2019-2024 | |
| Biogen, INC. | $101.11 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $99.82 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $86.20 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $71.49 | 2019-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Exeltis, USA INC. | $70.71 | 2022-2023 | Slynd |
| Mayne Pharma Commercial LLC | $69.55 | 2023 | |
| Myovant Sciences INC. | $57.90 | 2022 | |
| Optumhealth Care Solutions, LLC | $33.46 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Roche Diagnostics Corporation | $31.16 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $30.70 | 2024 | Perclot |
| Vertex Pharmaceuticals Incorporated | $28.96 | 2025 | |
| Boston Scientific Corporation | $28.58 | 2019 | |
| Scynexis, INC. | $26.05 | 2022 | |
| Therapeuticsmd, INC. | $22.21 | 2019 | |
| Heron Therapeutics, INC. | $20.57 | 2025 | Zynrelef |
| Convatec INC. | $18.63 | 2023 | |
| Minerva Surgical, INC | $18.36 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $17.37 | 2019 | |
| Allergan, INC. | $13.19 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.35 | 2019 | |
| Meditrina | $5.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.